Tepotinib clinical trials
Also written MSC2156119J, Tepmetko and EMD 1214063.
How each study uses tepotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tepotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 3 Feb 2021 · TEPMETKO · NDA 214096 (FDA, Drugs@FDA)
- European Union
- 16 Feb 2022 · Tepmetko · EMEA/H/C/005524 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 10
Merck KGaA, Darmstadt, Germany (5) · EMD Serono Research & Development Institute, Inc. (4) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (3) · M.D. Anderson Cancer Center (2) · Institute of Cancer Research, United Kingdom (1) · Fondazione per la Medicina Personalizzata (1) · EMD Serono (1) · Helsinki University Central Hospital (1)
Often tested with
Tested in the same studies.
Pembrolizumab (2) · Alectinib (2) · Cobimetinib (2) · HhAntag691 (2) · Trastuzumab (2) · Pertuzumab (2) · Entrectinib (2) · Atezolizumab (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tepotinib.
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
Studies
Open first, then newest update. How each study uses tepotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Tepotinib
- A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07619339Written as Tepotinib
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedRecruitingPhase 3Intergroupe Francophone de Cancerologie ThoraciqueNCT06908993Written as Tepotinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Tepotinib
- Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ CarcinomaRecruitingPhase 1/2Hallym University Medical CenterNCT05439993Written as Tepotinib plus paclitaxel
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT06083857Written as Tepotinib
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT03940703Written as Tepotinib
- Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingPhase 2EMD Serono Research & Development Institute, Inc.NCT02864992Written as Tepotinib
- POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingPhase 1Institute of Cancer Research, United KingdomNCT05782361Written as Tepotinib
- Tepotinib Hepatic Impairment TrialCompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT03546608Written as Tepotinib
- A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05120960Written as tepotinib
- Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05213481Written as Tepotinib
- Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05203822Written as Tepotinib (HydroChloride hydrate)
- Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of TepotinibCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04204902Written as Tepotinib 100 mg
- CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCTerminatedPhase 1/2Criterium, Inc.NCT04739358Written as Tepotinib
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431Written as Tepotinib
- Effect of a Proton Pump Inhibitor on the PK of TepotinibCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03531762Written as Tepotinib
- Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)TerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT04515394Written as Tepotinib
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)CompletedPhase 1/2Merck KGaA, Darmstadt, GermanyNCT01982955Written as Tepotinib
- c-Met Second-Line Hepatocellular CarcinomaCompletedPhase 1/2Merck KGaA, Darmstadt, GermanyNCT02115373Written as Tepotinib
See all 24 studies that test tepotinib →
Given beside what is tested · 4 — tepotinib is usual care or a partner of the new treatment
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT06031688Written as Tepotinib
- Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentRecruitingPhase 2Sehhoon ParkNCT06106802Written as Tepotinib
- Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran EtexilateCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03492437Written as Tepotinib
- Effect of Tepotinib on PK of CYP3A Substrate MidazolamCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03628339Written as Tepotinib
Codes
What other systems call tepotinib · ClinicalTrials.gg INT001334
- MeSH (NLM) C000707607tepotinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1IJV77EI07TEPOTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2477103One source FDA
- Wikidata Q27088961tepotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88314TepotinibOne source FDA
- DrugBank DB15133One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707607 | tepotinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1IJV77EI07 | TEPOTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2477103 | — | One source FDA |
| Wikidata | Q27088961 | tepotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88314 | Tepotinib | One source FDA |
| DrugBank | DB15133 | — | One source Wikidata |
Also registered as tepotinib hydrochloride (UNII VY5YX2TQ1F · RxNorm 2477104).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.